All In Biotech

Drug Trial Radar · NCT07102251

A Study to Evaluate the Safety, Tolerability, PK/PD of HEC-007 Injection in Healthy and Overweight/Obese Subjects

A Single-Center, Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HEC-007 Injection After Single-Dose Administration in Healthy Subjects and Multiple-Dose Administration in Overweight or Obese Subjects

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

126

Planned (sponsor's estimate)

Start

Sep 21, 2025

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Aug 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This trial adopts a single-center, randomized, double-blind, placebo-controlled, dose-escalation design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HEC-007 Injection after single-dose administration in healthy subjects and multiple-dose administration in overweight or obese subjects. The trial consists of two parts: Part A is a single ascending dose (SAD) study, planning to enroll 54 Chinese healthy subjects; Part B is a multiple ascending dose (MAD) study, planning to enroll 72 Chinese overweight or obese subjects.

Conditions

  • Healthy Subjects

Interventions

  • HEC-007 injectionDrug

    Single dose escalation of HEC-007 injection in healthy subjects

  • PlaceboDrug

    Single dose of placebo in healthy adults

  • HEC-007 injectionDrug

    Multiple dose escalation of HEC-007 injection in Overweight or Obese Subjects

  • PlaceboDrug

    Multiple dose of placebo in Overweight or Obese Subjects

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: Screening period up to day 43/day 113
  2. The maximum plasma concentration (Cmax)Time frame: Post-dose at day 1 to day 43/day 113
  3. Time to maximum plasma concentration (Tmax)Time frame: Post-dose at day 1 to day 43/day 113
  4. Terminal half-life (t1/2)Time frame: Post-dose at day 1 to day 43/day 113
  5. Apparent clearance (CL/F)Time frame: Post-dose at day 1 to day 43/day 113
  6. Apparent volume of distribution (Vz/F)Time frame: Post-dose at day 1 to day 43/day 113
  7. Area Under the PlasmaConcentration-TimeCurve (AUC) of HEC-007Time frame: Post-dose at day 1 to day 43/day 113
  8. Changes from baseline in Body WeightTime frame: Baseline period up to day 43/day 113
  9. Changes from baseline in waist circumferenceTime frame: Baseline period up to day 43/day 113
  10. Changes from baseline in Fasting Plasma GlucoseTime frame: Baseline period up to day 43/day 113
  11. Changes from baseline in Fasting InsulinTime frame: Baseline period up to day 43/day 113
  12. Changes from baseline in fasting blood lipidsTime frame: Baseline period up to day 43/day 113

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Second Affiliated Hospital of Anhui Medical University is a Grade A Tertiary General

    Hefei, Anhui, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.